Purification of the mitochondrial enzyme responsible for reduction of N-hydroxylated amidine prodrugs led to the identification of two newly discovered mammalian molybdenum-containing proteins, the mitochondrial amidoxime reducing components mARC-1 and mARC-2 ( 
Introduction
The enzymatic processes involved in the N-oxidative pathway are very well understood, whereas reduction pathways have been investigated in depth. The reduction of nitrogen-containing groups like aromatic nitro compounds, hydroxamic acids, oximes, tertiary Noxides, azo compounds, and N-hydroxyguanidines by the molybdenum hydroxylases aldehyde oxidase and xanthine oxidase have been described previously (Dambrova et al., 1998; Kitamura et al., 2006) . However, the activities were often only described for in vitro investigations under the exclusion of oxygen. The in vivo relevance is thus questionable. Microsomal and mitochondrial reductions of hydroxylamines and amidoximes that are O 2 -insensitive have been investigated by different groups (Kadlubar and Ziegler, 1974; Kurian et al., 2004 Kurian et al., , 2006 Andersson et al., 2005; Clement et al., 2005) , and it is well accepted that cytochrome b 5 and its reductase are involved in the reduction activities mentioned. The membrane-bound forms of these electron transport proteins are located in the mitochondrial outer membrane and the endoplasmic reticulum (Borgese et al., 1993) .
Investigation of the aerobic reduction of amidoxime structures led to the discovery of a hitherto unknown molybdenum-containing enzyme system (Havemeyer et al., 2006) . It was named "mitochondrial amidoxime reducing component" (mARC), because initially N-reduction of amidoxime structures was studied with this enzyme purified from mammalian liver mitochondria. After recombinant expression of human mARC (Gruenewald et al., 2008) , it became clear that besides sulfite oxidase, xanthine oxidoreductase and aldehyde oxidase, a fourth molybdenum-containing enzyme, exist. The human genome encodes for two homologous mARC proteins, mARC-1 and mARC-2 (designated as MOSC1 and MOSC2 in the databases). Both mARC homologs are able to reduce benzamidoxime as a model substrate in a reconstituted enzyme system together with NADH cytochrome b 5 and its reductase. We were able to demonstrate that this molybdenumcontaining enzyme system is responsible for amidoxime/N-hydroxyguanidine prodrug reduction to the pharmacologically active drug (Gruenewald et al., 2008) .
Although N-hydroxylated sulfonamides (sulfohydroxamic acids) have considerable potential to treat a variety of disorders, the reductive biotransformations of the compounds have been largely ignored. For example, N-substituted sulfonamides could act as nitric oxide donors (Shirota et al., 1999) , carbonic anhydrase (Mincione et al., 1998) , and tyrosinase inhibitors (Khan et al., 2005) . The recent development of a selective cyclooxygenase (COX)-2 inhibitor with a better adverse event profile, using valdecoxib as a lead compound, led to the corresponding N-hydroxylated sulfonamide (Erdélyi et al., 2008) . N-Hydroxy-valdecoxib is also a known metabolite of valdecoxib in humans (Yuan et al., 2002) . Recent in vivo studies of analgesic and anti-inflammatory effects showed that the N-hydroxylated analog is not only more potent, it also has a prolonged activity in comparison to valdecoxib. Contrary to expectations, in vitro COX-2 inhibitory potency of N-hydroxy-valdecoxib was low compared with valdecoxib (Erdélyi et al., 2008) . These data suggest that N-hydroxy-valdecoxib is bioactivated by reduction in vivo. Thus, N-hydroxy-valdecoxib could serve as a prodrug (Fig. 1) . If enzymatic metabolism is necessary for the pharmacological effect of valdecoxib, then it is necessary for further drug development to identify the reductive enzymes involved to be able to evaluate potential interspecies variability, genetic polymorphisms, and drug-drug interactions.
In the current study, the N-reductive substrate metabolism of Nhydroxy-sulfonamides in the recombinant and purified native porcine liver mARC-containing enzyme system is characterized by evaluating their kinetic parameters K m and V max . Furthermore, conversion rates of N-hydroxy-sulfonamide reduction by porcine liver mitochondria were compared with results obtained using purified native and recombinant enzymes.
In continuation of our drug metabolism studies, this report demonstrates that the described enzyme system is also able to reduce N-hydroxy-sulfonamides, such as N-hydroxy-valdecoxib, to their corresponding sulfonamides.
Materials and Methods
Chemicals. N-Hydroxy-benzenesulfonamide (NOHBSA) and N-hydroxy-4-toluenesulfonamide (NOHTSA) were synthesized according to the following procedure: 2.0 g (29 mmol) hydroxylamine-HCl was dissolved in refluxing methanol, and a solution of 0.6 g (26 mmol) sodium in 12.0 ml of ethanol was added. After cooling, the precipitated sodium chloride was filtered off, and in the remaining solution 1.7 g (10 mmol) of benzenesulfonyl chloride or 1.9 g (10 mmol) of toluenesulfonyl chloride was added. Most of the methanol was evaporated. The remainder was filtered, and the solution was evaporated to dryness in vacuo. The solid thus obtained was extracted three times with 5.0 ml of warm diethyl ether. Evaporation of the solvent afforded NOHBSA [melting point (m.p.) 120°C] (Smith and Hein, 1960) or NOHTSA (m.p. 143-144°C) (Przybylski and Kupryszwski, 1975) . In the same way, the corresponding sulfonamides benzenesulfonamide (BzSA) and 4-toluenesulfonamide (TSA) were obtained: 1.0 ml of benzenesulfonyl chloride (8 mmol) or 1.5 g of toluenesulfonyl chloride (8 mmol) was heated with 5.0 ml of concentrated ammonia solution for 15 min. Upon dilution with water, the corresponding sulfonamides precipitated [BzSA, m.p. 153°C (Johnson et al., 1978) and TSA, m.p. 141-142°C (Mcfarland et al., 1987) ]. The solid was recrystallized with ethanol and washed. N-Hydroxy-valdecoxib and valdecoxib were prepared according to the literature (Talley et al., 1996; Erdélyi et al., 2008) . Benzamidoxime (N-hydroxy-benzenecarboximidamide) was synthesized from benzonitrile and hydroxylamine as described previously (Krü ger, 1885). All other chemicals were obtained from Merck KGaA (Darmstadt, Germany), Sigma-Aldrich Chemie GmbH (Taufkirchen, Germany), or Promochem (Wesel, Germany).
Preparation of Subcellular Fractions. Mitochondria and microsomes were prepared from porcine liver (Hovius et al., 1990; Clement et al., 2005) .
Purification of Native Enzymes. Cytochrome b 5 was purified from porcine liver microsomes as described previously (Taniguchi et al., 1984; Clement et al., 1997) . NADH cytochrome b 5 reductase was purified from porcine liver microsomes, similar to the procedure described for the purification of NADH cytochrome P450 reductase (Yasukochi and Masters, 1976) . MARC was purified from porcine liver mitochondria, as described previously (Havemeyer et al., 2006) .
Expression and Purification of Recombinant Human mARC-1 and mARC-2. Full-length open reading frames of human mARC1 and mARC2 cDNAs of 1011 and 1105 base pairs, respectively, were truncated by polymerase chain reaction to remove the coding sequence for the putative NH 2 -terminal mitochondrial targeting sequences (according to GenPept accession numbers NP_073583 and NP_060368). The resulting 286 (mARC-1) and 285 (mARC-2) amino acids encoding cDNAs were cloned into the pQE80 expression plasmid (QIAGEN, Hilden, Germany), and proteins were expressed in Escherichia coli TP1000 cells (Palmer et al., 1996) and purified as described previously for full-length mARC-1 (Gruenewald et al., 2008) . Expression and purification of the N-terminally truncated recombinant proteins are described by Kotthaus and coworkers (Jü. Kotthaus, B. Wahl, A. Havemeyer, Jo. Kotthaus, D. Schade, D. Garbe-Schönberg, R. Mendel, F. Bittner, and B. Clement, manuscript submitted for publication).
Expression and Purification of Recombinant Human Cytochrome b 5 and Cytochrome b 5 Reductase. Expression of C-terminally truncated human cytochrome b 5 (GenPept accession number NP_085056) and human cytochrome b 5 reductase isoform 2 (GenPept accession number NP_015565) from expression plasmid pQE80 (QIAGEN) in E. coli DL41 cells and purification of the resulting recombinant protein were performed according to Kurian et al. (2004) . For some incubation studies, commercial available cytochrome b 5 (MoBiTec GmbH, Göttingen, Germany) was used.
Determination of Protein Concentration. Protein concentrations were determined using a BCA protein assay Kit (Pierce, Rockford, IL) following the manufacturer's instructions or using Roti Quant solution (Roth, Karlsruhe, Germany) according to Bradford (1976) .
Enzyme Assays. Cytochrome b 5 was estimated from the difference spectra between an oxidized and NADH reduced preparation (Estabrook and Werringloer, 1978) . NADH cytochrome b 5 reductase was determined by a modification of the ferricyanide reduction assay (Mihara and Sato, 1978) .
SDS-Polyacrylamide Gel Electrophoresis. SDS-polyacrylamide gel electrophoresis (PAGE) was carried out using a separation gel containing 12% polyacrylamide (Laemmli, 1970) . Silver staining was performed according to the manufacturer's directions (Silver Staining Kit, Protein Plus One; GE Healthcare, Chalfont St. Giles, UK). Standards and samples were pretreated with ␤-mercaptoethanol for 5 min at 100°C.
Molybdenum Cofactor Analysis. To identify the molybdenum cofactor coordinated by the purified mARC enzyme (porcine liver), the nit-1 reconstitution assay was used as described previously (Nason et al., 1971; Havemeyer et al., 2006) .
Incubations with N-Hydroxylated Substrates. Incubations were carried out under aerobic conditions at 37°C in a shaking water bath. Incubation mixtures contained 0.5 or 2 mM substrate and 1.0 mM NADH in a total volume of 150 l of potassium phosphate buffer (100 mM), pH 6.0 or 6.3. HPLC Method for the Separation of Benzamidoxime and Benzamidine. The separation was carried out as described previously (Clement et al., 2005) .
Results and Discussion
N-Hydroxy-valdecoxib is a novel COX-2 inhibitor in preclinical development. Although it shows only low COX-2 activity in vitro, it has good analgesic and anti-inflammatory potency in vivo (Erdélyi et al., 2008) . Therefore, a simple in vitro assay in an early state of drug development was needed to confirm the presumed in vivo reduction of N-hydroxy-valdecoxib to its active sulfonamide structure (Fig. 1) . In this report, we demonstrate the reduction of several N-hydroxy-sulfonamides (Fig. 2) , including N-hydroxy-valdecoxib, to their corresponding sulfonamides by porcine liver mitochondria. The following V max values were determined: 7.4 nmol sulfonamide/(min ⅐ mg mitochondrial protein) (reduction of N-hydroxy-valdecoxib, K m ϭ 0.6 mM), 15.6 nmol sulfonamide/(min ⅐ mg mitochondrial protein) (reduction of NOHTSA, K m ϭ 1.1 mM), and 20.6 nmol sulfonamide/(min ⅐ mg mitochondrial protein) (reduction of NOHBSA, K m ϭ 2.4 mM).
In conclusion, the analgesic and anti-inflammatory properties of N-hydroxy-valdecoxib together with its weak in vitro effect (Erdélyi et al., 2008) could be explained by the reduction of N-hydroxyvaldecoxib to the pharmacologically active sulfonamide. However, the formation of valdecoxib after in vivo administration of its Nhydroxy-sulfonamide derivative should also be demonstrated in further studies. To identify the enzyme system involved in the reduction of N-hydroxy-valdecoxib, the contribution of the molybdenum-containing enzyme system consisting of mARC, cytochrome b 5 , and NADH cytochrome b 5 reductase was included in this study.
For this purpose, the native mARC enzyme was purified from porcine liver mitochondria. The SDS-PAGE (Fig. 3) analysis showed an electrophoretically pure protein with the expected molecular mass of 35 kDa (Havemeyer et al., 2006) . The native enzyme was further characterized by its ability to reduce benzamidoxime in a reconstituted enzyme system together with NADH cytochrome b 5 and its reductase following Michaelis-Menten kinetic [K m ϭ 0.2 mM and V max ϭ 2.0 mol/(min ⅐ mg total protein)]. In addition, the presence of Moco was verified. The most sensitive assay for the detection of biologically active Moco is the so-called nit-1 assay (Nason et al., 1971) , which is based on the ability of any eukaryotic Moco source to dmd.aspetjournals.org complement the apo-NADPH nitrate reductase in crude extracts of the Neurospora crassa nit-1 mutant, which is deficient in Moco biosynthesis, thus reconstituting apoprotein (apo)-NADPH nitrate reductase activity. The purified mARC enzyme was able to reconstitute apo-NADPH nitrate reductase activity with a specific activity of 1.7 Ϯ 0.2 mol nitrite/(mg ⅐ min), confirming that this enzyme is a Mocobinding protein.
The reduction of N-hydroxy-valdecoxib to valdecoxib by native mARC (purified from porcine liver mitochondria) followed Michaelis-Menten kinetic with K m ϭ 1.5 mM and V max ϭ 51.2 nmol/(min ⅐ mg total protein). Thus, the specific activity was 7-fold enriched in the purified system compared with porcine liver mitochondria, with similar Michaelis-Menten constants (K m values).
Involvement of mARC in N-hydroxy-sulfonamide reduction was further verified by using recombinant enzymes that also catalyzed this transformation (Tables 1 and 2 ). Either no or only very little activity was detected if the two-component enzyme system consisted of only cytochrome b 5 and its reductase was incubated [maximum of 1.7 Ϯ 0.5 nmol sulfonamide/(min ⅐ mg total protein)]. Regarding the K m values, no substrate specificity for N-hydroxy-sulfonamides with both mARC homologs could be detected, but efficiency of catalysis (V max / K m ) is higher for mARC-1 than for mARC-2 (Table 2) .
It is not surprising that conversion rates of the recombinant molybdenum enzymes were 2-to 30-fold lower than that of purified native mARC protein from porcine liver mitochondria ( Table 1 ) or than that of mitochondria. These varying rate results may be due to the different origins of the mARC proteins (cDNA-expressed versus purified from porcine liver), which may be crucial for the absolute enzymatic activity. Perhaps imperfect folding and/or a lack of post-translational modifications will affect the activity. Furthermore, removal of the predicted N-terminal mitochondrial targeting sequences from recombinant mARC enzymes as well as removal of the hydrophobic anchor sequences of cytochrome b 5 and its reductase may influence efficiency. It can be assumed that electron transfer proteins must interact in a highly specific manner to allow effective electron transfer and that the hydrophobic domains afford an optimal complex formation of the enzymes. Nevertheless, the role of hydrophobic domains as well as the optimal stoichiometry of the three enzymes affecting conversion rates requires further analysis.
We cannot exclude the possibility that additional N-reductive enzymes may still play a minor role in the activation of N-hydroxyvaldecoxib. However, drug-drug interactions are unlikely to occur, because the prodrug-activation principle is not dependent on cytochrome P450 enzymes.
In summary, sufficient in vitro metabolism of N-hydroxy-sulfonamides, including N-hydroxy-valdecoxib, could be detected using recombinant enzymes. Therefore, the current study confirms the usefulness of the described recombinant enzymes for obtaining in vitro data for drug metabolism (Tables 1 and 2 ).
The reduction of N-hydroxy-sulfonamides supports previous studies (Gruenewald et al., 2008) stating that mARC plays a key role in the reductive biotransformation of structurally diverse N-hydroxylated compounds. Thus, the molybdenum-containing enzyme mARC is a protein that should be added to the list of prominent drug-metabolizing enzymes. 
Reduction of N-hydroxy-sulfonamides
A complete incubation mixture consisted of 200 pmol of cytochrome b 5 , 0.05 units of NADH cytochrome b 5 reductase, and 2.4 to 3 g of native mARC (purified from porcine liver mitochondria) or 10 to 30 g of mARC-1 or mARC-2 (human, recombinantly expressed), 0.5 mM N-hydroxyvaldecoxib, or 2 mM NOHBSA, respectively, NOHTSA, and 1.0 mM NADH in a total volume of 150 l of potassium phosphate buffer (100 mM 
